Twice weekly low dose interferon-beta-1a in relapsing-remitting multiple sclerosis (CROSBI ID 104132)
Prilog u časopisu | stručni rad
Podaci o odgovornosti
Debelić, Diana ; Jurjević, Ante ; Willheim, Ksenija ; Sepčić, Juraj
engleski
Twice weekly low dose interferon-beta-1a in relapsing-remitting multiple sclerosis
A randomised open-label study of interferon-beta-1a in 14 patients with relapsing-remitting multiple sclerosis was presented.Interferon-beta-1a was administered in doses of 11 mcg subcutaneously twice weekly for 12 months. The main objective of the study was to assess treatment efficacy in comparison with the 12 months pre-treatment period. The number of exacerbations decreased in 8, did not change in 3 and increased in 3 patients. There were 9 severe exacerbations in the pre-treatment year and only 1 in the treatment period. By the end of the therapy year disability decreased for one point in 0, 68 according to the Expanded Disability Status Scale outcome measure showing improvement of the major functional systems affected. Side effects, that were mild, appeared during the first three therapy months. The results suggest that interferon-beta -1a in dose of 11 mcg given twice weekly seems to be effective in reducing disability in relapsing-remitting multiple sclerosis.
interferon-beta-1a; relapsing remitting multiple sclerosis; multiple sclerosis; therapy
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano